Papers published by members our Cancer Informatics Research Group
2026
- Farič NA, Scherrens AL, Raemdonck E, Beernaert K, Cresswell K, Jacobs A, Lundeby T, Pardon K, Williams R, Van Landschoot F, de Vos-Geelen J, Ausen D, Urrizola A, Hjermstad MJ, Kaasa S, Fallon M, Deliens L, MyPath consortium, Absolom K, Andresen M, et al. Adaptation of digital integration of PROMs and PREMs in oncology during implementation: a scoping review. Supportive Care in Cancer. 2026;34(4):316.
- Walsh TS, Emerson L, Singleton J, Locherty R, Hope D, Cholbi S, Giddings A, Macdonald A, Lone N, Docherty AB, Mead G, Stanworth SJ, Drakesmith A, Roy NBA, Hall P, Neilson AR, Pollock R, Rodriguez A, Norrie J, Weir CJ, et al. Anaemia management with red blood cell transfusion to improve post-intensive care disability: Protocol for the ABC post-ICU randomised controlled trial. Journal of the Intensive Care Society. 2026;27(1):98-106.
- Cocco P, Bojke C, Hulme C, Hall PS, Hopkins A, Marshall A, Dunn JA, Meads D, Shinkins B. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis. British Journal of Cancer. 2026;134(2):252-258.
- Lundereng ED, Brkic A, Absolom K, Andvik E, Beernaert K, Cresswell K, Dajani OF, De Glas N, Fallon M, Freitas-Durks V, Guldhav KV, Hjermstad MJ, Kaasa S, Kurita GP, Lund JS, Mitrea N, Damink SO, Paulsen R, Pedersen GM, Skåre TS, et al. Balancing ideals and realities: health care professionals’ perspectives of and attitudes toward digital patient-centered cancer care. Quality of Life Research. 2026;35(3):76.
- López-Sánchez I, Palomar-Cros A, Claire R, Pérez-Crespo L, Giuliodori A, Koblbauer I, Dietz J, Elvidge J, Koh J, Golozar A, Ramirez-Anguita JM, Leis A, Mayer MA, Symmers N, Vallet MV, McLean C, Hall PS, Mosseveld M, Verhamme K, Enerly E, et al. Comorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe. The Lancet Regional Health - Europe. 2026;63:101585.
- Atter M, Bullen A, Cresswell K, Hall PS. Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: A Systematic Review and Parameter Extraction for Economic Modelling (Preprint). 2026.
- Abravan A, Fornacon-Wood I, Kingston R, Topping D, Price G. Environmental determinants of cancer outcomes: a scoping review. Radiotherapy and Oncology. 2026;217:111408.
- Wooller SK, Blake A, McCabe M, McLean C, Price G, Unsworth H, Van Hemelrijck M, Pearl FMG. From bench to byte: A UK perspective on data-driven cancer research. European Journal of Cancer. 2026;240:116751.
- McInerney S, Hall PS, Cresswell K. Large language models in oncology: promise, pitfalls, and the path to real-world adoption. ESMO Real World Data and Digital Oncology. 2026;13:100723.
- Haining K, Lemmon E, Hall P, Lone NI. Long-term costs associated with healthcare use of people with cancer in Scotland. The European Journal of Health Economics. 2026;27(1):1-15.
- Ellis L, Eversfield C, Gray E, Hall PS, Hiom S, Jones DA, Lee LY, McPhail S, Spencer K, Halloran C. Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England. British Journal of Cancer. 2026;135(2):265–272.
- Lundereng ED, Brkic A, Fallon M, Cresswell K, Deliens L, Pardon K, Beernaert K, Scherrens AL, Ausen D, Andresen M, Pedersen GM, Lykke C, Caraceni A, Cervantes A, Mitrea N, Olde Damink S, Hjermstad MJ, Kaasa S, Lundeby T, Absolom K, et al. Opportunities and challenges in implementing digital patient-centred cancer care in Europe—a qualitative study of several ESMO Designated Centres. ESMO Real World Data and Digital Oncology. 2026;12:100696.
- Angrisani A, Kirova Y, Abravan A, Becherini C, Benavente S, Castelo-Branco LS, Chalmers AJ, Christ SM, Deutsch E, Filippi AR, Hendriks LEL, Zolcsók Z, Illidge T, Rimner A, Herrera F, Ruysscher DD. Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy. Universität Zürich, ZORA. 2026.
2025
- Davie A, Traoré S, Badreldin W, Torstensson A, Cakar E, McCullough AC, Tempelaar S, Fenwick E, Hall PS. A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2–, Node-Positive, High-Risk Early Breast Cancer. Advances in Therapy. 2025;42(6):2767-2781.
- Mukhtar RA, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey JC, et al. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. npj Breast Cancer. 2025;11(1):14.
- Dunn JA, Donnelly P, Elbeltagi N, Marshall A, Hopkins A, Thompson AM, Audisio R, Pinder SE, Cameron DA, Hartup S, Turner L, Young A, Higgins H, Watson EK, Gasson S, Barrett-Lee PJ, Hulme C, Shinkins B, Hall PS, Evans A. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. The Lancet. 2025;405(10476):396-407.
- Loganath K, Lee KK, Oikonomidou O, Hall P, Mills NL, Joshi S, Singh T, McGillivray T, Semple S, Lang NN, Dweck MR, Henriksen PA. Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial. JACC: CardioOncology. 2025;7(6):725-735.
- Cottu P, Cheeseman S, Hall P, Wöckel A, Scholz CW, Bria E, Orlandi A, Ribelles N, Vallet MV, Niklas N, Hogg C, Aggarwal S, Moreira J, Lucerna M, Collin SM, Logue A, Long GIH. Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records. Breast Cancer Research and Treatment. 2025;209(2):419-430.
- Sears AJ, Wild SH, Mesa-Eguiagaray I, Hall PS, Figueroa JD. Breast cancer survival and mortality among women with type 2 diabetes: a retrospective cohort study. Scientific Reports. 2025;15(1):26144.
- Mesa-Eguiagaray I, Wild SH, Williams LJ, Jin K, Bird SM, Brewster DH, Hall PS, Figueroa JD. Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland. Breast Cancer Research. 2025;27(1):59.
- Stein RC, Marshall A, Makris A, Hughes-Davies L, Macpherson I, Hopkins AF, Cameron DA, Canney P, Earl HM, Rea DW, Bayani J, Hall PS, McCabe C, Donovan J, Harmer V, Pinder SE, Rooshenas L, Morgan A, Bartlett JMS, Dunn JA. Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study. ESMO Open. 2025;10:104744.
- Phillips I, Deans M, Walton A, Vallet MV, Mencnarowksi J, McMillan D, Peacock C, Hall P, O’Brien F, Stares M, Mackean M, Plant T, Grecian R, Allan L, Petrie R, Blues D, Haddad S, Barrie C. Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer. BMJ Supportive & Palliative Care. 2025;15(1):125-129.
- Davie A, Emde A, Durno N, Chattopadhyay D, Barlassina A, Hill D, Innes H, Hall PS. Healthstate Utilities for Hormone Receptor-Positive (HR+) Human Epidermal Growth Factor-Receptor 2 Negative (HER2-) Breast Cancer. Value in Health. 2025;28(12):S439.
- Paterson H, Vadiveloo T, Innes K, Balfour A, Atter M, Stoddart A, Cotton S, Arnott R, Aucott L, Batham Z, Foo I, MacLennan G, Nimmo S, Speake D, Norrie J. Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery. JAMA. 2025;333(1):39.
- Atter M, Stoddart A, Cotton S, Vadiveloo T, Innes K, Balfour A, Arnott R, Aucott L, Batham Z, Foo I, MacLennan G, Nimmo S, Speake D, Norrie J, Paterson H. Intravenous lidocaine for gut function recovery in colonic surgery: a health economic evaluation of the ALLEGRO randomised clinical trial. BMJ Open. 2025;15(2):e088298.
- Hatton NL, Baxter M, Lewis S, Hall PS, Spencer K. KERMIT: Performance indicators in electronic patient reported outcome measures: a modified Delphi. Journal of Patient-Reported Outcomes. 2025;9(1):81.
- Al-Shahi Salman R, Kitchen N, Forsyth L, Ganesan V, Hall PS, Harkness K, Hutchinson PJ, Lewis SC, Radatz MW, Turner C, Wade J, White DC, White PM. Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT. Health Technology Assessment. 2025;29(38):1-24.
- Atter MJ, Hall P, Evans RA, Norrie J, Cohen J, Williams B, Chaudhuri N, Bajwah S, Higginson I, Pearson M, Currow D, Stewart G, Fallon M, Johnson M. Morphine for chronic breathlessness (MABEL) in the UK: a health economic evaluation of a multisite, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial. BMJ Open. 2025;15(11):e102124.
- Johnson MJ, Williams B, Keerie C, Tuck S, Hart S, Bajwah S, Chaudhuri N, Pearson M, Cohen J, Evans RA, Currow DC, Higginson IJ, Hall P, Atter M, Norrie J, Fallon MT, Hart S, Barrett S, Bayes H, Stewart G, et al. Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial. The Lancet Respiratory Medicine. 2025;13(11):967-977.
- Phillips I, McDougall C, Walton A, Stares M, Hall P, Grecian R, O’Brien F, Mencnarowski J, MacCormick F, McLean G, Higgins S, McMillan D, Reid C, Allan L, Lim BJL, Barrie C. Multidisciplinary Prehabilitation Reduces Hospitalization Time and Suggests Improved Survival in Patients with Radiologically Diagnosed Lung Cancer. Cancers. 2025;17(20):3329.
- Tao Y, Lang CC, Petty RD, Hall PS, Baxter MA. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)—A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial. Cancers. 2025;17(4):601.
- Lucocq J, Erskine E, Hall P. The risk of contralateral breast cancer during long-term follow-up after breast conserving surgery to inform tailored surveillance protocols. European Journal of Surgical Oncology. 2025;51:109944.
2024
- Gray AJ, Oatey K, Grahamslaw J, Irvine SA, Cafferkey J, Kennel T, Norrie J, Walsh T, Lone N, Horner D, Appelboam A, Hall P, Skipworth RJE, Bell D, Rooney K, Shankar-Hari M, Corfield AR, on behalf of the Albumin, Balanced, and Crystalloid-Sepsis (ABC-Sepsis) Investigators. Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized Feasibility Trial— The ABC-Sepsis Trial*. Critical Care Medicine. 2024;52(10):1520-1532.
- Baxter MA, Spender LC, Cairns D, Walsh S, Oparka R, Porter RJ, Bray S, Skinner G, King S, Turbitt J, Collinson D, Miedzybrodzka ZH, Jellema G, Logan G, Kennedy RD, Turkington RC, McLean MH, Swinson D, Grabsch HI, Lord S, et al. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma. ESMO Open. 2024;9(5):103450.
- Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Wheatley D, Waters S, Palmieri C, Winter M, et al. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 2024;30(4):895-903.
- Reid EA, Abathun E, Diribi J, Mamo Y, Wondemagegnhu T, Hall P, Fallon M, Grant L. Early palliative care in newly diagnosed cancer in Ethiopia: feasibility randomised controlled trial and cost analysis. BMJ Supportive & Palliative Care. 2024;14(e1):e504-e507.
- Peters AL, Hall PS, Jordan LB, Soh FY, Hannington L, Makaranka S, Urquhart G, Vallet M, Cartwright D, Marashi H, Elsberger B. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective. The Breast. 2024;75:103728.
- Luta X, Diernberger K, Bowden J, Droney J, Howdon D, Schmidlin K, Rodwin V, Hall P, Marti J. Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis. BMJ Supportive & Palliative Care. 2024;14(e1):e807-e815.
- Diernberger K, Luta X, Bowden J, Fallon M, Droney J, Lemmon E, Gray E, Marti J, Hall P. Healthcare use and costs in the last year of life: a national population data linkage study. BMJ Supportive & Palliative Care. 2024;14(e1):e885-e892.
- Henriksen P, MacLean M, Atter M, Lewis S, Rodriguez A. High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT. Efficacy and Mechanism Evaluation. 2024:1-73.
- Downie S, Cherry J, Hall P, Stillie A, Moran M, Sudlow C, Simpson AHR. Metastatic bone disease: new quality performance indicator development. BMJ Supportive & Palliative Care. 2024;14(e3):e2619-e2631.
- Downie S, Chohan H, Ross L, McCann C, Hall P, Stillie A, Moran M, Sudlow C, Simpson AHR. New quality outcome indicators for bone metastases: expert consensus analysis of patients, their families and specialist healthcare professionals. BMJ Supportive & Palliative Care. 2024;14(e2):e2066-e2078.
- McManus RJ, Smith A, Temple E, Yu LM, Allen J, Doogue R, Ford GA, Glynn L, Guthrie B, Hall P, Hinton L, Hobbs FDR, Mant J, McKinstry B, Mead G, Morton K, Rai T, Rice C, Roman C, Stoddart A, et al. Self-monitoring of blood pressure following a stroke or transient ischaemic attack (TASMIN5S): a randomised controlled trial. BMC Cardiovascular Disorders. 2024;24(1):746.
- Bullen A, Ryan M, Ennis H, Gray E, Loría-Rebolledo LE, McIntyre M, Hall P. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment. BMJ Open. 2024;14(4):e076798.
- Lemmon E, Hanna C, Diernberger K, Paterson H, Wild S, Ennis H, Hall P. Variation in colorectal cancer treatment and outcomes in Scotland: real world evidence from national linked administrative health data. International Journal of Population Data Science. 2024;9(1):2179-2179.
2023
- Cafferkey J, Ferguson A, Grahamslaw J, Oatey K, Norrie J, Lone N, Walsh T, Horner D, Appelboam A, Hall P, Skipworth R, Bell D, Rooney K, Shankar-Hari M, Corfield A, Gray A. Albumin versus balanced crystalloid for resuscitation in the treatment of sepsis: A protocol for a randomised controlled feasibility study, “ABC-Sepsis”. Journal of the Intensive Care Society. 2023;24(1):78-84.
- McLean C, Sorokin A, Simpson TI, Armstrong JD, Sorokina O. BioNAR: an integrated biological network analysis package in bioconductor. Bioinformatics Advances. 2023;3(1):vbad137.
- Diernberger K, Clausen E, Murray G, Wee B, Kaasa S, Hall P, Fallon M. Cancer pain assessment and management: does an institutional approach individualise and reduce cost of care?. BMJ Supportive & Palliative Care. 2023;13(e3):e1258-e1264.
- Berdunov V, Millen S, Reynia S, Fryer N, Hall P, Perren T. Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer. European Journal of Surgical Oncology. 2023;49(5):e236.
- McLean C, Sorokin A, Armstrong JD, Sorokina O. Computational Pipeline for Analysis of Biomedical Networks with BioNAR. Current Protocols. 2023;3(12):e940.
- Phillips I, Petrie R, Allan L, Hall P, Walton A, McMillan D, Peacock C, Primrose L, Vallet MV, Mencnarowksi J, MacDonald N, Mackean M, Barrie C. Early prehabilitation in suspected locally advanced and metastatic lung cancer. BMJ Supportive & Palliative Care. 2023;13(e3):e908-e911.
- Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, et al. ESMO Guidance for Reporting Oncology real-World evidence (GROW). Annals of Oncology. 2023;34(12):1097-1112.
- Dunlop HM, Williams LJ, Hall PS, Barber M, Dodds C, Figueroa JD. Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland. Breast Cancer Research. 2023;25(1):106.
- Loan JJM, Bacon A, van Beijnum J, Bhatt P, Bjornson A, Broomes N, Bullen A, Bulters D, Cahill J, Chavredakis E, Colombo F, Danciut M, Digpal R, Edwards RJ, Ferguson L, Forsyth L, Fouyas I, Ganesan V, Grover P, Gurusinghe N, et al. Feasibility of comparing medical management and surgery (with neurosurgery or stereotactic radiosurgery) with medical management alone in people with symptomatic brain cavernoma – protocol for the Cavernomas: A Randomised Effectiveness (CARE) pilot trial. BMJ Open. 2023;13(8):e075187.
- Baxter MA, Spender LC, Walsh S, Bray S, Skinner G, King S, Hall PS, Seymour MJ, Petty RD, on behalf of the GO2 Investigators. Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial. Cancers. 2023;15(9):2591.
- Date K, Williams B, Cohen J, Chaudhuri N, Bajwah S, Pearson M, Higginson I, Norrie J, Keerie C, Tuck S, Hall P, Currow D, Fallon M, Johnson M. Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Research. 2023;9(4):00167-2023.
- Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, Stavert H, Broom A, Eddie L, Primrose L, McVicars H, McKay P, Borley A, Rowntree C, Lord S, Collins G, et al. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation. 2023;148(21):1680-1690.
- Goldstein DA, Ginsberg GM, Hofnung-Gabbay D, De Abreu Lourenco R, Loong HH, Goh BC, Chan KKW, Di Maio M, Perrone F, Hall PS, Zer A, Rosenbaum E. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors. JAMA Network Open. 2023;6(2):e230490.
- Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, Marshall H, Song M, Chan AT, Garrett WS, Yilmaz O, Drew DA, Collinson F, Cockbain AJ, Jones R, Loadman PM, Hall PS, Moriarty C, Cairns DA, Toogood GJ. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 2023;13(11):e077427.
- Stares M, Lewis G, Vallet M, Killean A, Tramonti G, Patrizio A, Mackean M, Harrow S, Barrie C, MacLennan K, Campbell S, Evans T, Tufail A, Edinburgh Cancer Informatics Programme, Hall P, Phillips I. Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre. Cancers. 2023;15(5):1431.
- Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Annals of Oncology. 2023;34(2):200-211.
- Purshouse K, Thomson JP, Vallet MV, Alexander L, Bonisteel I, Brennan M, Cameron DA, Figueroa JD, Furrie E, Haig P, Heck M, McCaughan H, Mitchell P, McVicars H, Primrose L, Silva I, Templeton K, Wilson N, Hall PS. The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti–Cancer Treatment. The Oncologist. 2023;28(3):e145-e155.
- Lim HF, Sharma A, Gallagher C, Hall P. Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer. Clinical Radiology. 2023;78(12):912-918.
- Diernberger K, Luta X, Bowden J, Droney J, Lemmon E, Tramonti G, Shinkins B, Gray E, Marti J, Hall PS. Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer type. International Journal of Population Data Science. 2023;8(1):1768-1768.
2022
- Fallon M, Dierberger K, Leng M, Hall PS, Allende S, Sabar R, Verastegui E, Gordon D, Grant L, Lee R, McWillams K, Murray GD, Norris L, Reid C, Sande TA, Caraceni A, Kaasa S, Laird BJA. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Annals of Oncology. 2022;33(12):1296-1303.
- Lemmon E, Birch R, Hall P, Morris E, Downing A. Analytical considerations when using the Scottish and English Cancer Registries for applied research: the case of colorectal cancer. International Journal of Population Data Science. 2022;7(3).
- Mesa-Eguiagaray I, Wild SH, Bird SM, Williams LJ, Brewster DH, Hall PS, Figueroa JD. Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. Breast Cancer Research and Treatment. 2022;194(2):463-473.
- Hanna CR, Lemmon E, Hall PS, Ennis H, Morris E, McLoone P, Boyd KA, Jones RJ. Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment (SCOT) Trial Findings in colorectal cancer at a National Level. Clinical Oncology. 2022;34(9):554-560.
- Berdunov V, Millen S, Paramore A, Hall P, Perren T, Brown R, Griffin J, Reynia S, Fryer N, Longworth L. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. Journal of Medical Economics. 2022;25(1):591-604.
- Reid E, Abathun E, Diribi J, Mamo Y, Wondemagegnhu T, Hall P, Fallon M, Grant L. Early integrated palliative care in patients newly diagnosed with cancer in Ethiopia: a randomised controlled trial and cost–consequence analysis. The Lancet Global Health. 2022;10:S13.
- Pearce J, Swinson D, Cairns D, Nair S, Baxter M, Petty R, Seymour M, Hall P, Velikova G. Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. Journal of Geriatric Oncology. 2022;13(3):287-293.
- Newall AT, Beutels P, Tuffaha HW, Hall PS, Jit M. How can early stage economic evaluation help guide research for future vaccines?. Vaccine. 2022;40(2):175-177.
- Luta X, Diernberger K, Bowden J, Droney J, Hall P, Marti J. Intensity of care in cancer patients in the last year of life: a retrospective data linkage study. British Journal of Cancer. 2022;127(4):712-719.
- Várnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, Booth S, Campton NA, Collins GP, Hughes DJ, Kulasekararaj AG, Lee AJX, Olsson-Brown AC, Sharma-Oates A, Van Hemelrijck M, Lee LYW, Kerr R, Middleton G, Cazier JB, UKCCMP Team, et al. Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Network Open. 2022;5(2):e220130.
- Chitkara A, Mesa-Eguiagaray I, Wild SH, Hall PS, Cameron DA, Sims AH, Figueroa JD. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study. Breast Cancer Research and Treatment. 2022;196(2):379-387.
- Swann OV, Lone NI, Harrison EM, Tomlinson LA, Walker AJ, Seaborne MJ, Pollock L, Farrell J, Hall PS, Seth S, Williams TC, Preston J, Ainsworth JS, Semple FF, Baillie JK, Katikireddi SV, Akbari A, Lyons R, Simpson CR, Semple MG, et al. Studying the Long-term Impact of COVID-19 in Kids (SLICK). Healthcare use and costs in children and young people following community-acquired SARS-CoV-2 infection: protocol for an observational study using linked primary and secondary routinely collected healthcare data from England, Scotland and Wales. BMJ Open. 2022;12(11):e063271.
- Lemmon E, Connearn E, Hall P, Morris E, UK Colorectal Intelligence Hub And Yorkshire Cancer Research Bowel Cancer Improvement Programme Public-Patient Group. Successful public and patient involvement in bowel cancer research using linked administrative health data. International Journal of Population Data Science. 2022;7(3).
- Anderson RA, Lambertini M, Hall PS, Wallace WH, Morrison DS, Kelsey TW. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. European Journal of Cancer. 2022;173:113-122.
- Lemmon E, Rutherford A, Hall P, Bell D, Henderson D, Downing A, Clark S. The use of social care services by individuals aged 50 and over diagnosed with colorectal cancer in Scotland: a linked data study. International Journal of Population Data Science. 2022;7(3).
- Spencer K, Defourny N, Tunstall D, Cosgrove V, Kirkby K, Henry A, Lievens Y, Hall P. Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. Radiotherapy and Oncology. 2022;166:180-188.
2021
- Hall CC, Skipworth RJE, Blackwood H, Brown D, Cook J, Diernberger K, Dixon E, Gibson V, Graham C, Hall P, Haraldsdottir E, Hopkinson J, Lloyd A, Maddocks M, Norris L, Tuck S, Fallon MT, Laird BJA. A randomized, feasibility trial of an exercise and nutrition‐based rehabilitation programme (ENeRgy) in people with cancer. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(6):2034-2044.
- Hanna C, Lemmon E, Ennis H, Jones R, Hay J, Halliday R, Clark S, Morris E, Peter H. Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science. 2021;6(1):1654-1654.
- Downing A, Hall P, Birch R, Lemmon E, Affleck P, Rossington H, Boldison E, Ewart P, Morris EJA. Data Resource Profile: The COloRECTal cancer data repository (CORECT-R). International Journal of Epidemiology. 2021;50(5):1418-1418k.
- Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. JAMA Oncology. 2021;7(6):869.
- Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery. 2021;11(11):2796-2811.
- Donáth J, Balla B, Pálinkás MR, Rásonyi R, Vastag G, Alonso N, Prieto BL, Vallet MV, Ralston SH, Poór G. Pattern of SQSTM1 Gene Variants in a Hungarian Cohort of Paget’s Disease of Bone. Calcified Tissue International. 2021;108(2):159-164.
- McCabe C, Tramonti G, Sutton A, Hall P, Paulden M. Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. PharmacoEconomics. 2021;39(1):19-24.
- Maeda Y, Gray E, Figueroa JD, Hall PS, Weller D, Dunlop MG, Din FVN. Risk of missing colorectal cancer with a COVID-adapted diagnostic pathway using quantitative faecal immunochemical testing. BJS Open. 2021;5(4):zrab056.
- Vallet MV, Sophocleous A, Törnqvist AE, Azfer A, Hof RVT, Albagha OM, Ralston SH. Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation. Calcified Tissue International. 2021;109(1):92-102.
- Hulbert-Williams NJ, Leslie M, Hulbert-Williams L, Koczwara B, Watson EK, Hall PS, Ashley L, Coulson NS, Jackson R, Millington S, The Finding My Way UK Trial Steering Group, Beatty L. The Finding My Way UK Clinical Trial: Adaptation Report and Protocol for a Replication Randomized Controlled Efficacy Trial of a Web-Based Psychological Program to Support Cancer Survivors. JMIR Research Protocols. 2021;10(9):e31976.
- Baxter MA, Murphy J, Cameron D, Jordan J, Crearie C, Lilley C, Sadozye A, Maclean M, Hall P, Phillips A, Greger A, Madeleine J, Petty RD. The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. British Journal of Cancer. 2021;124(8):1353-1356.
- Gray E, Figueroa JD, Oikonomidou O, MacPherson I, Urquhart G, Cameron DA, Hall PS. Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open. 2021;6(6):100331.
2020
- Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel LS, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology. 2020;38(5):423-433.
- Mesa-Eguiagaray I, Wild SH, Rosenberg PS, Bird SM, Brewster DH, Hall PS, Cameron DA, Morrison D, Figueroa JD. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. British Journal of Cancer. 2020;123(5):852-859.
- Tzolos E, Adamson PD, Hall PS, Macpherson IR, Oikonomidou O, MacLean M, Lewis SC, McVicars H, Newby DE, Mills NL, Lang NN, Henriksen PA. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Clinical Oncology. 2020;32(5):292-297.
- McCabe C, Paulden M, Awotwe I, Sutton A, Hall P. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. PharmacoEconomics. 2020;38(2):135-141.
- Reid E, Abathun E, Diribi J, Mamo Y, Hall P, Fallon M, Wondemagegnhu T, Grant L. Rationale and study design: A randomized controlled trial of early palliative care in newly diagnosed cancer patients in Addis Ababa, Ethiopia. Contemporary Clinical Trials Communications. 2020;18:100564.
- Franks KN, McParland L, Webster J, Baldwin DR, Sebag-Montefiore D, Evison M, Booton R, Faivre-Finn C, Naidu B, Ferguson J, Peedell C, Callister MEJ, Kennedy M, Hewison J, Bestall J, Gregory WM, Hall P, Collinson F, Olivier C, Naylor R, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. European Respiratory Journal. 2020;56(5):2000118.
- Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, et al. Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment. 2020;24(40):1-190.
- Conefrey C, Donovan JL, Stein RC, Paramasivan S, Marshall A, Bartlett J, Cameron D, Campbell A, Dunn J, Earl H, Hall P, Harmer V, Hughes-Davies L, Macpherson I, Makris A, Morgan A, Pinder S, Poole C, Rea D, Rooshenas L. Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer. Clinical Oncology. 2020;32(6):382-389.
- Hamilton P, Wilson F, Chinnadurai R, Sinha S, Singh M, Ponnusamy A, Hall P, Dhaygude A, Kanigicherla D, Brenchley P. The investigative burden of membranous nephropathy in the UK. Clinical Kidney Journal. 2020;13(1):27-34.
- Lemmon E. Utilisation of Personal Care Services in Scotland: The Influence of Unpaid Carers. Journal of Long-Term Care. 2020(2020):54.
2019
- Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet. 2019;393(10191):2599-2612.
- Gray E, Marti J, Wyatt JC, Brewster DH, Hall PS, SATURNE advisory group. Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. PLOS Medicine. 2019;16(12):e1003006.
- Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Effectiveness and Resource Allocation. 2019;17(1):5.
- Abel L, Shinkins B, Smith A, Sutton AJ, Sagoo GS, Uchegbu I, Allen AJ, Graziadio S, Moloney E, Yang Y, Hall P. Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives. Medical Decision Making. 2019;39(7):857-866.
- Spencer K, Le Calvez K, Hall P, Velikova G, Henry A, Morris E, Williams M. Fractionation and early mortality in palliative radiotherapy: Insights from the national radiotherapy dataset. Clinical Oncology. 2019;31:e14.
- Smith A, Shinkins B, Hulme C, Hall P, Messenger M. Methods to assess the impact of test measurement uncertainty on downstream clinical outcomes: A case study of faecal calprotectin (FC) for the diagnosis of Inflammatory Bowel Disease (IBD). Clinica Chimica Acta. 2019;493:S353-S354.
- Spencer K, Velikova G, Henry A, Westhoff P, Hall PT, van der Linden YM. Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study. International Journal of Radiation Oncology*Biology*Physics. 2019;105(3):559-566.
- Gray E, Marti J, Brewster DH, Wyatt JC, Piaget-Rossel R, Hall PS. Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. Journal of Clinical Epidemiology. 2019;109:125-132.
- MacLullich AM, Shenkin SD, Goodacre S, Godfrey M, Hanley J, Stíobhairt A, Lavender E, Boyd J, Stephen J, Weir C, MacRaild A, Steven J, Black P, Diernberger K, Hall P, Tieges Z, Fox C, Anand A, Young J, Siddiqi N, et al. The 4 ‘A’s test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technology Assessment. 2019;23(40):1-194.
- von Strauss M, Marti WR, Mujagic E, Coslovsky M, Diernberger K, Hall P, Zeindler J, Salm LA, Soysal SD, Mechera R, von Holzen U, Weber WP. The impact of surgical site infections on hospital contribution margin—a European prospective observational cohort study. Infection Control & Hospital Epidemiology. 2019;40(12):1374-1379.
- Rooshenas L, Scott LJ, Blazeby JM, Rogers CA, Tilling KM, Husbands S, Conefrey C, Mills N, Stein RC, Metcalfe C, Carr AJ, Beard DJ, Davis T, Paramasivan S, Jepson M, Avery K, Elliott D, Wilson C, Donovan JL, Rogers CA, et al. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology. 2019;106:108-120.
- Lemmon E. Utilisation of Personal Care Services in Scotland: the Influence of Unpaid Carers. International Journal of Population Data Science. 2019;4(3).
2018
- Hall CC, Norris L, Dixon L, Cook J, Maddocks M, Graham C, Tuck S, Haraldsdottir E, Brown D, Lloyd A, Finucane A, Hall P, Diernberger K, Skipworth RJE, Fallon M, Laird BJ. A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol. Pilot and Feasibility Studies. 2018;4(1):192.
- Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A, Stein R, Donovan JL, Beard D, Carr A, Cook J, Cooper C, Dean B, Donovan JL, Gray A, Gwilym S, et al. An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology. 2018;99:75-83.
- Sarfaty M, Hall PS, Chan KKW, Virik K, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. European Urology. 2018;74(1):57-62.
- Mackenzie SP, Carter TH, Jefferies JG, Wilby JBJ, Hall P, Duckworth AD, Keating JF, White TO. Discharged but not dissatisfied: outcomes and satisfaction of patients discharged from the Edinburgh Trauma Triage Clinic. The Bone & Joint Journal. 2018;100-B(7):959-965.
- Gray E, Marti J, Brewster DH, Wyatt JC, Hall PS, the SATURNE Advisory Group. Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data. British Journal of Cancer. 2018;119(7):808-814.
- Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac’h JY. Real-world treatment in patients with HER2+ metastatic breast cancer. Breast Cancer Research and Treatment. 2018;168(1):197-205.
2017
- Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, Roy R, Dent J, Cheeseman S, Last K, Seymour MT. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer. 2017;116(4):472-478.
- Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The Oncologist. 2017;22(6):694-699.
- Smith AF, Hall PS, Hulme CT, Dunn JA, McConkey CC, Rahman JK, McCabe C, Mehanna H. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European Journal of Cancer. 2017;85:6-14.
- Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology. 2017;28(4):754-760.
- Szabados B, Gomez De Liano Lista A, Wimalasingham A, De Bruijn R, Haanen J, Blank C, Hall P, Staehler M, Chowdhury S, Hopkins T, Powles T, Bex A. Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer. European Urology Supplements. 2017;16(3):e1604.
- Mehanna H, McConkey CC, Rahman JK, Wong WL, Smith AF, Nutting C, Hartley AG, Hall P, Hulme C, Patel DK, Zeidler SVV, Robinson M, Sanghera B, Fresco L, Dunn JA. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment. 2017;21(17):1-122.
- Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, Campbell A, Macpherson IR, Dan Rea, Francis A, Earl H, Morgan A, Stein RC, McCabe C. Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. Value in Health. 2017;20(10):1311-1318.
2016
- Goldstein DA, Chen Q, Ayer T, Chan KK, Virik K, Hammerman A, Brenner B, Flowers C, Hall P. Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis. Journal of Clinical Oncology. 2016;34(15_suppl):6518-6518.
- Bartlett JMS, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC, et al. Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute. 2016;108(9):djw050.
- Kennedy MPT, Hall PS, Callister MEJ. Factors affecting hospital costs in lung cancer patients in the United Kingdom. Lung Cancer. 2016;97:8-14.
- Johnson OA, Hall PS, Hulme C. NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data. PharmacoEconomics. 2016;34(2):107-114.
- Marti J, Hall P, Hamilton P, Lamb S, McCabe C, Lall R, Darbyshire J, Young D, Hulme C. One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. Journal of Intensive Care. 2016;4(1):56.
- Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A, on behalf of the OPTIMA Trial Management Group. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment. 2016;20(10):1-202.
- Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. New England Journal of Medicine. 2016;374(15):1444-1454.
- Marti J, Hall PS, Hamilton P, Hulme CT, Jones H, Velikova G, Ashley L, Wright P. The economic burden of cancer in the UK: a study of survivors treated with curative intent. Psycho-Oncology. 2016;25(1):77-83.
2015
- Afshar M, Hamilton P, Seligmann J, Lord S, Baxter P, Marples M, Stark D, Hall PS. Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?. Cancer Investigation. 2015;33(8):347-353.
- Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, Marti J, Smith AF, Mason H, Velikova G, Ashley L, Wright P. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. British Journal of Cancer. 2015;112(5):948-956.
Last updated 2026-07-08.